Strides Pharma Science Ltd · NSE:STAR
Strides Pharma Science — Strides Arcolab — Merger or Acquisition (January 2012)
10 slides from Strides Pharma Science's merger presentation, Jan 24, 2012
Slide 1: Sale of generic pharmaceutical operations in Australia and Southeast Asia for AU$375 million
Sale of generic pharmaceutical operations in Australia and Southeast Asia for AU$375 million Analyst Presentation 24 January 2012 inspiring synergies
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which has been prepared by Strides Arcolab Limited (the "Company"), has been prepared for information purposes only and is not, and is not intended to be, an offer, or solicitation of offer, or invitation or recommendatio
Slide 3: Transaction overview
Transaction overview On Tuesday, 24 January 2012, Strides Arcolab sold Ascent Pharmahealth, its generic pharmaceutical operations in Australia and Southeast Asia, to Watson Pharmaceuticals All-cash transaction valuing Ascent at an enterprise vale of AU$ 375 million (US$393 million at current exchang
Slide 4: Overview of Ascent Pharmahealth Limited
Overview of Ascent Pharmahealth Limited Australia Contribution to Group 2011 guidance Top 5 generic pharmaceutical company Consolidated revenue Second largest pharmacy field force US$ 482 million Robust portfolio of marketed and pipeline products across generics, OTC, skin care and dermatology as we
Slide 5: Transaction rationale and use of proceeds
Transaction rationale and use of proceeds Executing on the announced strategy to focus on core high-growth 1 Agila business 2 Monetising significant value creation at Ascent 3 Strengthening balance sheet 5
Slide 6: Executing on the announced strategy to focus on core high-growth Agila business
1 Executing on the announced strategy to focus on core high-growth Agila business Growth capital to drive forward strategy for Agila Specialities Attain global leadership Better placed to fund position in the steriles future capital sector expenditure in Agila Potential re-rating given Enhanced mana
Slide 7: Monetising significant value creation at Ascent
2 Monetising significant value creation at Ascent Strides has significantly increased the value of Ascent since initial investment in 2008 R&D collaboration with Strategic combination Strides, improved sourcing with Drug Houses of through site transfer and Australia (DHA) in improved bargaining Sout
Slide 8: Valuation achieved is at the top end of the very best transactions in the industry
2 Monetising significant value creation at Ascent Valuation achieved is at the top end of the very best transactions in the industry Transaction value / LTM EBITDA ratio (1) Acquiror / target Ascent’s 2011 EBITDA based on contribution of 18%–20% to Strides’ consolidated 2011 guidance of US$ 96 milli
Slide 9: Strengthen balance sheet
3 Strengthen balance sheet Use of proceeds Proceeds being used to Pay down US$250 million debt, of which US$120 million will be used for redemption of the convertible bond due in June-2012 Growth Capital for Agila These funds will allow Strides to radically improve its leverage position, reducing it
Slide 10: Thank You
Thank You 88 Strides
Strides Arcolab — Merger or Acquisition (January 2012) on 6ix